Related Experiment Video

Updated: Aug 8, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions

Pamela Ouyang1, Erin D Michos, Richard H Karas

  • 1Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. pouyang@jhmi.edu

Journal of the American College of Cardiology
|May 10, 2006
PubMed

Insights

Hormone therapy may benefit younger women for cardiovascular disease prevention, but trials in older women show no benefit and potential harm. Further research is needed on hormone therapy and women's heart health.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Women's Health

Background:

  • Cardiovascular disease (CVD) is the leading cause of death in U.S. women.
  • Women develop CVD approximately a decade later than men, potentially due to protective effects of female hormones lost after menopause.

Purpose of the Study:

  • To review scientific evidence on hormone therapy (HT) and cardiovascular risk in women.
  • To synthesize findings from basic science, animal, observational, and clinical trials.
  • To identify unanswered questions regarding HT and CVD in women.

Main Methods:

  • Review of existing literature from basic science, animal studies, observational research, and randomized controlled trials (RCTs).

Main Results:

  • Early HT initiation in perimenopausal women or before significant atherosclerosis may offer cardiovascular benefits.
  • RCTs in older women show no benefit for primary or secondary CVD prevention and suggest potential harm.
  • Conflicting evidence exists regarding the timing and safety of HT for cardiovascular health.

Conclusions:

  • The role of hormone therapy in cardiovascular disease prevention for women is complex and depends on factors like age and timing of initiation.
  • Current evidence does not support routine use of HT for CVD prevention in postmenopausal women.
  • Further research is essential to clarify the risks and benefits of HT in specific female populations.

More Related Videos

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System02:47

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...